Guide til OLIVER’S og vores ingredienser OLIVER’S PETFOOD Havre er et enestående valg af kulhydrat og det bærende element i Stiftet i 1998 og i dag Nordens største direkte foderleverandør. En vores TRIPLE CARB SOURCE™. Med sit lave glykæmiske niveau af årsagerne til denne position er vores indstilling og fokus på ingre-(<50) sikres et stabilt blodsukker niveau. (Ikke i SEL
Bardzo tanie apteki z dostawą w całej Polsce kupic levitra i ogromny wybór pigułek.
Womancareva.comThe New York Times
The Diabetes Dilemma for Statin Users
By ERIC J. TOPOL
We’re overdosing onlowering statins, and the consequence could be a This past week, the Food and Drug Administration raised questions about the side effects of these drugs and developed new labels for these medications that wil now warn of the risk ofand The announcement said the risk was “smal ” and should not material y affect the use of these medications. The data are somewhat ambiguous for memory loss. But the magnitude of the problem for diabetes becomes much more apparent with careful examination of the data from large clinical have been available since the 1980s but their risk of inducing diabetes did not surface for nearly 20 years. When al the data available from multiple studies was pooled in 2010 for more than 91,000 patients randomly assigned to be treated with a statin or a sugar pil (placebo), the risk of developing diabetes with any statin was one in every 255 patients treated. But this figure is misleading since it includes weaker statins like Pravachol and Mevacor — which were introduced earlier and do not carry any clear-cut risk. It is only with the more potent statins (now known as simvastatin), (atorvastatin) and(rosuvastatin) — particularly at higher doses, that the risk of diabetes shows up. The cause and effect was unequivocal because the multiple large trials of the more potent statins had a consistent excess of diabetes.
For those statins, the higher the dose, the more diabetes, though we don’t have enough data yet to say with precision at which dose excess diabetes showed up for each drug. What we do know is that diabetes showed up. The numbers increase to one in 167 for patients taking 20 mil igrams of Crestor, and up to one in 125 for intensive statin treatments involving drug strategies to markedly lower cholesterol levels. Let’s just round this off and say that one in every 200 patients treated with any of the three most potent statins will get the side effect of diabetes. That’s quite a conservative number because diabetes was not even being careful y looked for in most of the trials. And we have data for only 5 years of treatment; it might be worse with longer statin therapy.
More than 20 mil ion Americans take statins. That would equate to 100,000 new statin- induced diabetics. Not a good thing for the public health and certainly not good for the individual affected with a new serious chronic il ness.
If there were a major suppression of heart attacks or strokes or deaths, that might be justified. But in patients who have never had heart disease and are taking statins to lower their risk (so-cal ed primary prevention), the reduction of heart attacks and other major events is only 2 per 100. And we don’t know who the 2 per 100 patients are who benefit or the one per 200 who wil get diabetes! Moreover, the margin of benefit to risk What should people who are taking statins do? If they are prescribed for someone who has already had heart disease or a stroke, the benefit is overriding — no changes are suggested. But in the vast majority of people who take statins — those who have never had any heart disease — there should be a careful review of whether the statin is necessary, in light of the risk of diabetes and the relatively smal benefit that can be derived. Beyond that, a dose reduction or use of a less potent statin should be We need to find out why statins cause diabetes and, ideal y, through genomics we could determine who is at risk for this important side effect. But to date nothing has been done to sort this out — despite the fact that the market for statins is wel over $20 bil ion per year. There are thousands of blood samples sitting in company freezers around the world that could potential y provide the answers.
The announcement, medication label change and health advisory by the F.D.A. were long overdue, and have brought this important public health issue to light. The information that we have does not support that this is a “smal ” problem unless one considers more than 100,000 new diabetics insignificant. The problem of statin-induced diabetes cannot be underplayed while the country is being overdosed.
is a cardiologist at the Scripps Clinic, a professor of genomics at the Scripps Research Institute and the author of “The Creative Destruction of Medicine.”
The best ICHO-tasks of the last years According to the decision of the work shop of Amsterdam the delegation leaders of 8countries made an attempt to rank the ICHO-tasks of the years 1980 ~ 1990 into thecategoriesexcellent / good / not so good / not acceptableThe following pages indicate the ”top-twelve”, i.e. is the best tasks of the last years. Thiscollection should be an aid for the IC